Literature DB >> 18401570

[Replacement therapy with adrenal steroids].

S Hahner1, B Allolio.   

Abstract

Replacement with adrenal steroids comprises treatment with glucocorticoids, mineralocorticoids and adrenal androgen precursors, mainly in patients with adrenal insufficiency. Attention has also been directed to replacement treatment with glucocorticoids in critically ill patients or with dehydroepiandrosterone (DHEA) in elderly people with an age related decline of DHEA/DHEAS levels. Despite the use of current replacement concepts well-being is often not fully restored in patients with adrenal insufficiency. Innovations comprise the development of new delayed release glucocorticoid preparations that allow to better mimic the circadian cortisol secretion and may have the potential to improve the treatment of patients with adrenal insufficiency. Recent results from the CORTICUS study have not confirmed previous beneficial results and have led to restrictions in the use of hydrocortisone substitution therapy in patients with septic shock. Treatment with the androgen precursor DHEA in patients with adrenal insufficiency may improve quality of life. However, in patients with an age related decline of DHEA levels, the available evidence does not support the use of DHEA replacement as an anti aging treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18401570     DOI: 10.1007/s00108-008-2122-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

1.  Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone.

Authors:  W Oelkers; S Diederich; V Bähr
Journal:  J Clin Endocrinol Metab       Date:  1992-07       Impact factor: 5.958

2.  Dehydroepiandrosterone replacement in women with adrenal insufficiency.

Authors:  W Arlt; F Callies; J C van Vlijmen; I Koehler; M Reincke; M Bidlingmaier; D Huebler; M Oettel; M Ernst; H M Schulte; B Allolio
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

3.  Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial.

Authors:  Kristian Løvås; Gennet Gebre-Medhin; Thor S Trovik; Kristian J Fougner; Sverre Uhlving; Bjørn G Nedrebø; Ole L Myking; Olle Kämpe; Eystein S Husebye
Journal:  J Clin Endocrinol Metab       Date:  2003-03       Impact factor: 5.958

4.  Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial.

Authors:  Sjoerd W van Thiel; Johannes A Romijn; Alberto M Pereira; Nienke R Biermasz; Ferdinand Roelfsema; Albert van Hemert; Bart Ballieux; Johannes W A Smit
Journal:  J Clin Endocrinol Metab       Date:  2005-03-29       Impact factor: 5.958

5.  Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism.

Authors:  R Libè; L Barbetta; C Dall'Asta; F Salvaggio; C Gala; P Beck-Peccoz; B Ambrosi
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

6.  Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement.

Authors:  Antonia M Brooke; Leonila A Kalingag; Farideh Miraki-Moud; Cecilia Camacho-Hübner; Katharine T Maher; Dorothy M Walker; Joy P Hinson; John P Monson
Journal:  J Clin Endocrinol Metab       Date:  2006-07-18       Impact factor: 5.958

7.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

8.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

9.  Continuous subcutaneous hydrocortisone infusion in Addison's disease.

Authors:  Kristian Løvås; Eystein S Husebye
Journal:  Eur J Endocrinol       Date:  2007-07       Impact factor: 6.664

10.  Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements.

Authors:  Wiebke Arlt; Carmen Rosenthal; Stefanie Hahner; Bruno Allolio
Journal:  Clin Endocrinol (Oxf)       Date:  2006-04       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.